{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:15:39Z","timestamp":1779387339019,"version":"3.53.1"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Older patients age &gt;60 years with advanced-stage cHL have historically had poorer outcomes, attributed to comorbid conditions, performance status, and chemotherapy intolerance. The use of an anthracycline-based chemotherapy backbone has shown strong correlation with improved survival, and the intent of treatment remains curative even in the older population. Strategies to help mitigate treatment toxicity to allow for treatment continuation remain one of the greatest concerns in the treatment of older cHL patients. Avoidance of bleomycin, use of G-CSF in brentuximab vedotin (BV)-AVD, and the use of comprehensive geriatric assessments to assess fitness have allowed for more tailored therapy with improved outcomes in older cHL patients. In clinical practice, identification of comorbid conditions or functional deficits using a comprehensive geriatric assessment allows the provider to intervene earlier, modify risk factors, provider supportive care, and possibly modify therapy based on frailty index. Despite these advances, a standardized frontline treatment regimen has not been universally recognized, but recent advances with the use of targeted therapies such as BV or nivolumab have demonstrated improved outcomes. The recent subset analysis of older patients with advanced-stage cHL treated with N-AVD is the first to suggest an OS benefit in oHL patients, with an acceptable toxicity and tolerability profile. The S1826 study assessed patient-reported QOL measures longitudinally and found that older patients treated with BV-AVD experienced more self-reported neuropathy, diarrhea, and arthralgias\/myalgias compared with those on N-AVD. The self-reported tolerability and physician-reported toxicity profile of the S1826 regimen with N-AVD supports the emerging use of N-AVD as frontline therapy in older patients with advanced-stage cHL. Further research is ongoing to tailor treatments for older patients with cHL.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000828","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:28Z","timestamp":1779386428000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Older Patients With Hodgkin Lymphoma: A Contemporary Review"],"prefix":"10.1097","volume":"32","author":[{"given":"Meghana","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-9040","authenticated-orcid":false,"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R1-20260521","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin\u2019s disease in patients above the age of 60: a population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann Oncol"},{"key":"R2-20260521","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-20260521","first-page":"450","article-title":"Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients","volume":"81","author":"Levis","year":"1996","journal-title":"Haematologica"},{"key":"R6-20260521","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin- containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/1097-0142(19930301)71:5<1857::AID-CNCR2820710524>3.0.CO;2-B","article-title":"Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease","volume":"71","author":"Mir","year":"1993","journal-title":"Cancer"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0959-8049(99)00267-1","article-title":"Long-term survival in Hodgkin\u2019s disease patients: a comparison of relative survival in patients in trials and those recorded in population-based cancer registries","volume":"36","author":"Roy","year":"2000","journal-title":"Eur J Cancer"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of ABVD and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"7-8","key":"R10-20260521","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/028418602321028283","article-title":"Patients above sixty years lymphoma treated with a new strategy of age with Hodgkin\u2019s","volume":"41","author":"Enblad","year":"2002","journal-title":"Acta Oncol"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13440","article-title":"Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma","volume":"24","author":"Ro\u017eman","year":"2022","journal-title":"Oncol Lett"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s44313-025-00084-4","article-title":"Treatment of older patients with Hodgkin lymphoma","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/j.seminhematol.2024.05.004","article-title":"The Management of older patients with Hodgkin lymphoma: implications of S1826","volume":"61","author":"McKenna","year":"2024","journal-title":"Semin Hematol"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/hematology.2019000028","article-title":"Management of older Hodgkin lymphoma patients","volume":"2019","author":"Evens","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin\u2013AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J Clin Oncol"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdg065","article-title":"The effect of Epstein\u2013Barr virus status on outcome in age-andsex-defined subgroups of patients with advanced Hodgkin\u2019s disease","volume":"14","author":"Flavell","year":"2003","journal-title":"Ann Oncol"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1097-0142(19840301)53:5<1202::AID-CNCR2820530530>3.0.CO;2-L","article-title":"Prognostic factors in Hodgkin\u2019s disease with special reference to age","volume":"53","author":"Wedelin","year":"1984","journal-title":"Cancer"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1097-0142(19900401)65:7<1635::AID-CNCR2820650730>3.0.CO;2-M","article-title":"Survival of the older patient compared with the younger patient with Hodgkin\u2019s disease. Influence of histologic type, staging, and treatment","volume":"65","author":"Walker","year":"1990","journal-title":"Cancer"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"e2014053","DOI":"10.4084\/mjhid.2014.053","article-title":"Prognostic factors in Hodgkin lymphoma","volume":"6","author":"Cuccaro","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced- stage Hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the HoLISTIC consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"M1068","DOI":"10.1093\/gerona\/59.10.M1068","article-title":"Measuring medical burden using CIRS in older veterans enrolled in UPBEAT, a psychogeriatric treatment program: a pilot study","volume":"59","author":"Mistry","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the Cumulative Illness Rating Scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/aol-22-6","article-title":"Clinical geriatric assessment in older patients with lymphoma: a narrative review","volume":"6","author":"Soverini","year":"2022","journal-title":"Ann Lymphoma"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy\u2013a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"R31-20260521","first-page":"1645","article-title":"Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment","author":"Caillet","year":"2014","journal-title":"Clin Interv Aging"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djs285","article-title":"Use of geriatric assessment for older adults in the oncology setting: a systematic review","volume":"104","author":"Puts","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hon.2715","article-title":"Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma","volume":"38","author":"Galli","year":"2020","journal-title":"Hematol Oncol"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"e2128373","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of treatment intensity with survival in older patients with Hodgkin lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jgo.2021.07.003","article-title":"Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose- intense chemotherapy","volume":"12","author":"Kumar","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"R38-20260521","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.2005.00457.x","article-title":"An international approach to the treatment of Hodgkin\u2019s disease in the elderly: launch of the SHIELD study programme","volume":"75","author":"Proctor","year":"2005","journal-title":"Eur J Haematol"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jha2.202","article-title":"Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000\u20132014, focusing on patients aged > 60 years","volume":"2","author":"Wahlin","year":"2021","journal-title":"EJHaem"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clml.2018.11.009","article-title":"Prognostic utility of the IPS 3 score for predicting outcomes in advanced Hodgkin lymphoma","volume":"19","author":"Ganesan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br J Haematol"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"e2300255","DOI":"10.1200\/CCI.23.00255","article-title":"Machine learning\u2013based survival prediction models for progression-free and overall survival in advanced-stage Hodgkin lymphoma","author":"Rask Kragh Jorgensen","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","article-title":"Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century","volume":"10","author":"Pulte","year":"2020","journal-title":"Blood Cancer J"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET- CT for staging and early response: results from the Response- Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"R49-20260521","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06598.x","article-title":"G-CSF is not necessary to maintain over 99% dose\u2013intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis","volume":"137","author":"Evens","year":"2007","journal-title":"Br J Haematol"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"Boll","year":"2013","journal-title":"J Clin Oncol"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"key":"R52-20260521","first-page":"46","article-title":"Probability of cure in elderly Hodgkin\u2019s disease patients","volume":"79","author":"Levis","year":"1994","journal-title":"Haematologica"},{"key":"R53-20260521","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"key":"R55-20260521","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"key":"R56-20260521","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"key":"R57-20260521","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","article-title":"Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era","volume":"61","author":"Taparra","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R58-20260521","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte- colony stimulating growth factor (dagger)","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R59-20260521","first-page":"200","article-title":"Impact of preexisting heart failure on treatment and outcomes in older patients with hodgkin lymphoma","volume":"6","author":"Upshaw","year":"2024","journal-title":"Cardio Oncol"},{"key":"R60-20260521","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"R61-20260521","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"R62-20260521","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged > \/ = 60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"R63-20260521","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","article-title":"Brentuximab vedotin","volume":"124","author":"Ansell","year":"2014","journal-title":"Blood"},{"key":"R64-20260521","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R65-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"R66-20260521","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/hematology.2023000511","article-title":"Management of limited-stage Hodgkin lymphoma","volume":"2023","author":"Al-Juhaishi","year":"2023","journal-title":"Hematology"},{"key":"R67-20260521","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"R68-20260521","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R69-20260521","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mdl094","article-title":"A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients","volume":"17","author":"Landgren","year":"2006","journal-title":"Ann Oncol"},{"key":"R70-20260521","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"R71-20260521","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u2265 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"R72-20260521","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"R73-20260521","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"key":"R74-20260521","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"R75-20260521","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with hodgkin lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"key":"R76-20260521","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"key":"R77-20260521","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+ AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"R78-20260521","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2025-151","article-title":"3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma","volume":"146","author":"Herrera","year":"2025","journal-title":"Blood"},{"key":"R80-20260521","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"Boll","year":"2011","journal-title":"Blood"},{"key":"R81-20260521","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.HS9.0000890820.12468.10","article-title":"P063: trial in progress: individualized immunotherapy in early-stage unfavorable Hodgkin lymphoma-the investigator-initiated phase II GHSG INDIE trial","volume":"6","author":"Brockelmann","year":"2022","journal-title":"Hemasphere"},{"key":"R83-20260521","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO-25-00439","article-title":"Positron emission tomography-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone in older patients with advanced-stage classic Hodgkin lymphoma: a prospective, multicenter, single-arm, phase II cohort of the German Hodgkin study group HD21 trial","volume":"43","author":"Ferdinandus","year":"2025","journal-title":"J Clin Oncol"},{"key":"R84-20260521","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"key":"R85-20260521","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"key":"R86-20260521","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.HS9.0000890896.83681.49","article-title":"T082: AVD-a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients","volume":"6","author":"Overgaard","year":"2022","journal-title":"Hemasphere"},{"key":"R87-20260521","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1182\/bloodadvances.2022008258","article-title":"The outcome of older adults with classic Hodgkin lymphoma in British Columbia","volume":"6","author":"Cheng","year":"2022","journal-title":"Blood Adv"},{"key":"R88-20260521","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R89-20260521","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/clinpract15010015","article-title":"Impact of comorbidities on prognosis and treatment outcomes in elderly patients with Hodgkin lymphoma","volume":"15","author":"Tothfalusi","year":"2025","journal-title":"Clin Pract"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:37Z","timestamp":1779386437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000828","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-02-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}